Details of the Drug
General Information of Drug (ID: DMYRLA0)
| Drug Name |
ZARAGOZIC ACID B
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
Zaragozic acid B; UNII-2AF560R2HC; 2AF560R2HC; CHEMBL504845; 146389-61-9; SCHEMBL6130350; GTPL6061; BDBM50292415; L-glycero-D-altro-Pentadec-14-en-7-ulo-7,4-furanosonic acid, 2,7-anhydro-3,4-di-C-carboxy-8,9,10,12,13,14,15-heptadeoxy-10,12-dimethyl-15-phenyl-, 5-(6,12-tetradecadienoate), (5(6E,12E),7S,10xi,11xi,12xi)-; (1R,2S,3S,5S,6R,7R)-2,6-dihydroxy-5-[(E)-4-hydroxy-3,5-dimethyl-8-phenyloct-7-enyl]-7-[(6E,12E)-tetradeca-6,12-dienoyl]oxy-4,8-dioxabicyclo[3.2.1]octane-1,2,3-tricarboxylic acid
|
||||||||||||||||||
| Indication |
|
||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||
| #Ro5 Violations (Lipinski): 5 | Molecular Weight (mw) | 730.8 | |||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 6 | ||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 23 | ||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 6 | ||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 13 | ||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||
|
||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||
References


